
Specialty· July 7, 2026 · 21 min read
Voranigo (vorasidenib) Glioma Access: Pricing, Biomarker Testing, and Payer PA
By Ran Chen#Oncology#Orphan Drug#Prior Authorization
FDA-approved companion diagnostics, biomarker testing requirements, liquid biopsy, and how diagnostic requirements shape drug access workflows.




